billHR8065Event Thursday, March 26, 2026Analyzed

Restoring Executive Branch Authorities to Oversee Offices of the United States Attorneys Act of 2026

Neutral

Summary

HR8065, the Restoring Executive Branch Authorities to Oversee Offices of the United States Attorneys Act of 2026, was ordered reported out of the House Judiciary Committee on a party-line 12-11 vote. The bill eliminates the authority of U.S. district courts to appoint interim U.S. Attorneys, shifting that power entirely to the executive branch. This is a structural governance change with no direct market impact, as it does not authorize or appropriate any funding, affect any publicly traded company's revenue, or alter any sector's regulatory landscape.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR8065 is a governance bill with zero direct market impact.
  • 2.No publicly traded company is affected by this legislation.
  • 3.The bill's narrow committee passage and lack of Senate companion indicate low probability of enactment.

Market Implications

This bill has no market implications. It does not authorize spending, create contracts, or alter any industry's regulatory environment. Retail investors should ignore this legislation as it pertains to portfolio decisions.

Full Analysis

HR8065 is a procedural bill that amends the process for filling vacancies in U.S. Attorney positions. Currently, if a U.S. Attorney vacancy lasts beyond 120 days, the relevant U.S. district court can appoint an interim replacement. This bill removes that court authority, leaving the appointment power solely with the Attorney General (executive branch). The bill was introduced by Rep. Derek Schmidt (R-KS-2) on March 24, 2026, referred to the House Judiciary Committee, and ordered reported (amended) on March 26, 2026, by a 12-11 vote along party lines. It awaits floor action in the House. There is no companion bill in the Senate. The bill authorizes zero funding—it is a change in appointment procedure, not a spending authorization. No publicly traded company is affected because the bill does not alter any commercial activity, regulatory compliance, or government contracting. The legislative path forward is uncertain given the narrow committee vote and lack of Senate action. The bill's impact is purely structural within the Department of Justice.

Key Legislators

Rep. Schmidt, Derek [R-KS-2]

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →